1. Name and Address of Reporting Person
   Secora Michael
   (Last)       (First)       (Middle)
   C/O RECURRENCE PHARMACEUTICALS
   41 S. RIO GRANDE STREET
   SALT LAKE CITY, UT 84101

2. Title of Security (Instr. 3)
   3. Transaction Date (Month/Day/Year)
   4. Transaction Code (Instr. 8)
   5. Description of Derivative Securities Acquired (e.g., puts, calls, warrants, options, convertible securities)
   6. Price of Derivative Security (Instr. 9)
   7. Nature of Indirect Beneficial Ownership (Instr. 4)

1. Title of Security (Instr. 3)
   Class A Common Stock
   Class A Common Stock
   Class A Common Stock
   Class A Common Stock

2. Transaction Date (Month/Day/Year)
   08/15/2023
   08/15/2023
   08/15/2023
   08/16/2023
   08/16/2023

3. Transaction Code (Instr. 8)
   P(1)
   M(2)
   S(2)
   M(2)
   S(2)

4. Description of Derivative Securities Acquired (e.g., puts, calls, warrants, options, convertible securities)
   Stock Option (Right to Buy)
   Stock Option (Right to Buy)
   Stock Option (Right to Buy)
   Stock Option (Right to Buy)
   Stock Option (Right to Buy)

5. Nature of Indirect Beneficial Ownership (Instr. 4)
   685,177 D
   1,485,135 D
   1,410,135 D
   116,684 D
   404,857 D

Explanation of Responses:
1. Represents shares that have been withheld by the Issuer to satisfy its tax withholding and remittance obligations in connection with the net settlement of restricted stock units.
2. Transaction is pursuant to a 10b5-1 trading plan adopted by the Reporting Person on March 1, 2023.
3. This transaction was executed in multiple trades at prices ranging from $8.14 to $9.55. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
4. This transaction was executed in multiple trades at prices ranging from $8.86 to $8.91. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
5. The option, originally for 1,125,000 shares, vests as to one forty-eighth (1/48th) of the shares subject to the award one month after March 1, 2020, and one forty-eighth (1/48th) of the shares subject to the award shall vest each month thereafter.
6. The option, originally for 1,500,000 shares, vests incrementally upon satisfaction of certain liquidity events.
7. The option vests as to one forty-eighth (1/48th) of the shares subject to the option on March 1, 2022, and one forty-eighth (1/48th) of the shares subject to the option shall vest each month thereafter.

8. The option vests as to one forty-eighth (1/48th) of the shares subject to the option on March 1, 2023, and one forty-eighth (1/48th) of the shares subject to the option shall vest each month thereafter.

Remarks:

/s/ Jonathan Golightly, attorney-in-fact 08/17/2023

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see instruction 4 (b)(v).


Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.